INTRODUCTION
============

The American College of Cardiology (ACC)/American Heart Association (AHA) and the European Society of Cardiology (ESC) have developed evidence-based guidelines for the treatment of heart failure (HF) to assist clinicians in clinical decision-making by describing acceptable approaches to the diagnosis, management, and prevention of specific diseases or conditions.[@B1][@B2] In chronic HF with reduced ejection fraction (HFrEF), evidence-based benefit on outcome is documented for angiotensin-converting enzyme inhibitors (ACEI), angiotensin-receptor II blockers (ARB), β-blockers, mineralocorticoid receptor antagonists (MRA), angiotensin receptor neprilysin inhibitors (ARNI), and ivabradine. However, acute heart failure (AHF) is characterized by rapid worsening of symptoms and signs of HF. Although survival rates have improved, mortality is still high, typically greater than 4%. However, most morbidity and mortality of hospitalized AHF occurs early after index hospital discharge.[@B3][@B4] Hospitalized HF patients have 30-day readmission rates from 20% to 27%, with mortality rate reaching up to 12.2% at 30-days.[@B5][@B6] Once the patient is stabilized, the priority should transition to initiation of chronic medical therapy. Modalities initiated in the hospital engender increased outpatient adherence and improved outcomes. Therefore, comprehensive strategies must focus on factors during hospitalization and during the early recovery period soon after discharge to target stressors that contribute to patient vulnerability. The guideline-directed therapy in HF inpatient is associated with post-discharge mortality or re-hospitalization.[@B7][@B8][@B9] AHF has two forms according to the time course of heart failure: newly arisen ("*de novo*") AHF and acutely decompensated chronic heart failure (ADCHF).[@B1][@B2] Acute and chronic HF differ both in their temporal course and treatment.[@B3][@B10] However, there are limited data regarding the prognostic implications of guideline-directed therapy according to the temporal course of HF. We assessed the relationship between guideline-directed therapy at discharge and 60-day relevant patient clinical outcomes, including all-cause mortality, re-hospitalization because of aggravated HF, and composite endpoint of mortality or HF hospitalization in *de novo* AHF and ADCHF separately.

METHODS
=======

Study population
----------------

We used the registry of Korean Acute Heart Failure (KorAHF), which is a multicenter prospective cohort study. Between March 2011 and February 2014, the registry prospectively enrolled 5,625 consecutive patients admitted for treatment of AHF from 10 tertiary university hospitals. Patients were followed-up until 2018. The registry included patients with signs or symptoms of HF who met at least one of the following inclusion criteria: 1) lung congestion or 2) objective findings of left ventricular systolic dysfunction (LVSD) or structural heart disease. Detailed information on the study design and results of the KorAHF registry have been described previously.[@B11]

Adherence to guideline-directed therapy
---------------------------------------

Guideline-directed therapy was defined by ACC/AHA and ECS guidelines.[@B1][@B2] Numerators were defined as HF patients who were prescribed each medication and denominator as HF patients with LVSD and without contraindication for medication. The adherence to guideline-directed therapy was assessed by the ratio of the numerator to the dominator.[@B12][@B13] Of these guideline-directed therapies, we excluded ARNI and ivabradine because this therapy was not available in Korea during the study period.

The adherence to guideline-directed therapy was defined as follows: 1) β-blocker therapy for LVSD: percentage of patients who were prescribed β-blocker therapy with bisoprolol, carvedilol, sustained-release metoprolol succinate, or nebivolol at hospital discharge. Because the 2016 ESC guidelines for HF recommend β-blockers, including nebivolol, for the treatment of HFrEF, patients prescribed nebivolol were defined as numerators.[@B14] Patients not eligible for β-blocker therapy were those with systolic blood pressure \< 90 mmHg or resting heart rate \< 60 bpm at discharge.[@B2] An equivalent dose of carvedilol was calculated for bisoprolol- and nebivolol-treated subjects (dose × 5), and for metoprolol-treated subjects (dose/4), again taking into account several possible confounders[@B15]; 2) ACEI or ARB therapy for LVSD: percentage of patients who were prescribed ACEI or ARB therapy at hospital discharge. Patients not eligible for ACEI or ARB therapy were those with systolic blood pressure \< 90 mmHg or serum creatinine \> 2.5 mg/dL or serum K ≥ 5.0 mmol/L at discharge.[@B2] Equivalent doses of ramipril were calculated for ACEI, and equivalent doses of candesartan were calculated for ARB.[@B16]

An additional performance measure for MRA was developed, excluding patients with documented MRA contraindications or intolerance (serum K ≥ 5.0 mmol/L or creatinine \> 2.5 mg/dL at discharge).[@B2]

Clinical outcomes
-----------------

The follow-up data were collected from the patients by the attending physician and stored in a web-based case report form. The outcome data of subjects who had not been followed-up were ascertained by telephone interview. In addition, the outcome data of patients lost to follow-up were collected from the National Death Records. All clinical events, such as death and re-hospitalization were monitored and verified by a Clinical Event Committee comprising independent experts in HF who did not participate in patient enrolment for the study.[@B11] The outcomes were 60-day all-cause mortality, re-hospitalization because of aggravated HF, and composite endpoint of mortality or HF hospitalization.

Statistical analysis
--------------------

Statistical analyses were conducted by the Center of Biomedical Data Science, Yonsei University, Wonju College of Medicine. Continuous variables are expressed as mean ± SD and categorical variables as percentages. For continuous variables, the independent t-test was used, and for dichotomous variables, the χ^2^ test was adopted, as appropriate. The Kaplan-Meier method was used to report survival curves and estimate the mean survival, and the 95% confidence interval (CI) and the log rank test were applied. Cox proportional hazards regression models were used to estimate hazard ratios (HRs) and their 95% CIs. Models were adjusted for gender; age; history of hypertension, diabetes mellitus, ischemic heart disease, and chronic obstructive pulmonary disease; New York Heart Association functional class; systolic blood pressure; heart rate; creatinine; presence of atrial fibrillation at admission; and LVEF. Model discrimination was assessed using Harrell\'s C-statistic. In all cases, a *P* value \< 0.05 was considered statistically significant. Statistical analyses were performed using SAS 9.4 (SAS Inc., Cary, NC, USA) and R software version 3.4.3 (R Foundation for Statistical Computing, Vienna, Austria).

Ethics statement
----------------

The study protocol was approved by the ethics committee at each hospital and the Wonju Christian Hospital, Wonju College of Medicine, Yonsei University (Wonju, Korea; Approval No. CR311003), and written informed consent was obtained from each patient or their relative or legal representative.

RESULTS
=======

Baseline characteristics of the study population and clinical outcomes
----------------------------------------------------------------------

Of 5,625 patients, we selected patients with LVSD, which was defined as LVEF \< 40% using echocardiography. After excluding 272 patients without quantitative LVEF data and 83 heart transplantation candidates, 2,769 patients were analyzed ([Fig. 1](#F1){ref-type="fig"}). Patients were classified by the attending physician according to the contemporary guidelines on AHF, based on the clinical presentation at admission. ADCHF was defined as worsening of HF in patients with a previous diagnosis or hospitalization for HF. *De novo* AHF, defined as AHF in patients with no prior history of HF[@B14] included 1,417 patients. There were 1,352 patients with ADCHF. Demographic characteristics were significantly different between the 2 groups. Patients with ADCHF were older and had lower body weight, blood pressure, and heart rate than did patients with *de novo* AHF. ADCHF patients had higher rates of comorbid disease. Electrocardiographically, atrial fibrillation and left bundle branch block were more prevalent in ADCHF. At admission, sodium and hemoglobin levels were lower and creatinine and N-terminal pro-brain natriuretic peptide (NT-proBNP) levels were higher in patients with ADCHF. On echocardiography, patients with ADCHF had a more deteriorated heart function ([Table 1](#T1){ref-type="table"}). In patients with ADCHF, 60-day rehospitalization (14.3% vs. 6.8%; *P* \< 0.001), mortality (8.2% vs. 5.9%; *P* = 0.02), and composite endpoint (20.6% vs. 11.8%; *P* \< 0.001) rates were higher compared with those in patients with *de novo* HF ([Supplementary Table 1](#S1){ref-type="supplementary-material"}).

![Flow diagram of patients included.\
LVEF = left ventricular ejection fraction.](jkms-34-e133-g001){#F1}

###### Baseline characteristics of the study population

![](jkms-34-e133-i001)

  Characteristics                           *De novo* AHF (n = 1,417)               ADCHF (n = 1,352)    *P* value             
  ----------------------------------------- --------------------------------------- -------------------- --------------------- ------------
  Demographic characteristic at admission                                                                                      
                                            Gender, men                             873 (61.6)           816 (60.4)            0.50
                                            Age, yr                                 63.9 ± 15.6          69.0 ± 13.2           \< 0.001
                                            Height, cm                              162.6 ± 9.2          161.2 ± 9.3           \< 0.001
                                            Weight, cm                              62.5 ± 14.1          59.9 ± 12.6           \< 0.001
                                            Body mass index, kg/m^2^                23.5 ± 4.0           22.9 ± 3.7            \< 0.001
                                            Systolic blood pressure, mmHg           133.9 ± 30.1         125.7 ± 28.2          \< 0.001
                                            Diastolic blood pressure, mmHg          83.9 ± 20.0          76.8 ± 17.1           \< 0.001
                                            Heart rate, beat/min                    99.3 ± 25.1          92.5 ± 24.5           \< 0.001
                                            NYHA functional class                                                              0.13
                                                                                    Class II             206 (14.5)            182 (13.5)
                                                                                    Class III            503 (35.5)            530 (39.2)
                                                                                    Class IV             708 (50.0)            640 (47.3)
  Comorbidity                                                                                                                  
                                            Hypertension                            725 (51.2)           817 (60.4)            \< 0.001
                                            Diabetes mellitus                       460 (32.5)           566 (41.9)            \< 0.001
                                            Ischemic heart disease                  227 (16.0)           604 (44.7)            \< 0.001
                                            Chronic kidney disease                  137 (9.7)            271 (20.0)            \< 0.001
                                            Chronic obstructive pulmonary disease   123 (9.0)            165 (12.2)            0.01
  Medication at admission                                                                                                      
                                            ACEI                                    96 (26.0)            273 (74.0)            \< 0.001
                                            ARB                                     243 (17.0)           494 (36.5)            \< 0.001
                                            β-blocker                               188 (13.3)           561 (41.5)            \< 0.001
                                            MRA                                     110 (7.8)            437 (32.3)            \< 0.001
  Etiology of heart failure                                                                              \< 0.001              
                                            Ischemic heart disease                  538 (38.0)           598 (44.2)            
                                            Valvular heart disease                  63 (4.4)             137 (10.1)            
                                            Cardiomyopathy                          447 (31.5)           402 (29.7)            
  ECG characteristics at admission                                                                                             
                                            Atrial fibrillation at admission        362 (25.5)           454 (33.6)            \< 0.001
                                            Left bundle branch block                90 (6.4)             128 (9.5)             \< 0.001
                                            Right bundle branch block               64 (4.5)             93 (6.9)              0.01
  Laboratory characteristics at admission                                                                                      
                                            Na, mmol/L                              138.2 ± 4.2          136.9 ± 4.8           \< 0.001
                                            K, mmol/L                               4.3 ± 0.7            4.5 ± 0.7             \< 0.001
                                            Albumin, g/dL                           3.7 ± 0.5            3.7 ± 0.5             0.91
                                            Hemoglobin, g/dL                        13.1 ± 2.4           12.4 ± 2.2            \< 0.001
                                            Creatinine, mg/dL                       1.4 ± 1.6            1.6 ± 1.5             \< 0.001
                                            hs-CRP, mg/dL                           2.1 ± 3.5            2.1 ± 4.1             0.96
                                            NT-proBNP, pg/mL                        9,308.9 ± 11,845.1   11,506.2 ± 11,171.0   \< 0.001
                                            BNP, pg/mL                              1,597.9 ± 1,466.3    1,636.0 ± 1,381.7     0.67
                                            CK-MB, ng/mL                            9.4 ± 27.8           5.2 ± 12.0            \< 0.001
                                            Troponin I, mg/mL                       3.2 ± 22.2           0.6 ± 2.8             \< 0.001
  Echocardiographic characteristics                                                                                            
                                            LVEF, %                                 27.3 ± 7.9           26.2 ± 7.9            \< 0.001
                                            LVEDV, mL                               166.5 ± 68.2         188.0 ± 76.5          \< 0.001
                                            LVESV, mL                               119.6 ± 55.6         138.2 ± 64.1          \< 0.001
                                            LA dimension, mm                        46.1 ± 8.0           49.9 ± 9.2            \< 0.001

Values are presented as number (%) or mean ± standard deviation, unless otherwise indicated.

AHF = acute heart failure, ADCHF = acutely decompensated chronic heart failure, NYHA = New York Heart Association, ACEI = angiotensin-converting enzyme inhibitor, ARB = angiotensin-receptor II blocker, MRA = mineralocorticoid receptor antagonists, ECG = electrocardiography, hs-CRP = high-sensitivity C-reactive protein, NT-proBNP = N-terminal-proBNP, BNP = B-type natriuretic peptide, CK-MB = creatinine kinase-MB, LVEF = left ventricular ejection fraction, LVEDV = left ventricular end diastolic volume, LVESV = left ventricular end systolic volume, LA = left atrium.

Discharge medication and guideline adherence
--------------------------------------------

Compliance rates for performance measures ranged from high for ACEI or ARB (84.5%) to low for β-blocker (64.5%) and MRA therapy (58.1%) in patients with *de novo* AHF. Compliance with ACEI or ARB (75.2%), β-blocker (52.9%), and MRA (56.1%) decreased in patients with ADCHF ([Supplementary Table 2](#S2){ref-type="supplementary-material"}). With regard to medication at discharge, the calculated equivalent doses for ACEI, ARB, β-blockers, and MRA were compared, and they did not differ between the 2 groups ([Table 2](#T2){ref-type="table"}).

###### Medical therapy at discharge

![](jkms-34-e133-i002)

  Variables                *De novo* AHF (n = 1,417)           ADCHF (n = 1,352)                   *P* value                  
  ------------------------ ----------------------------------- ----------------------------------- ------------- ------------ ------
  ACEI or ARB                                                                                                                 
                           ACEI at discharge                                                                                  
                                                               Ramipril equivalent dose, mg        2.9 ± 2.3     3.0 ± 2.3    0.65
                                                               Titration to target dose, No. (%)   32 (2.3)      22 (1.6)     0.23
                           ARB at discharge                                                                                   
                                                               Candesartan equivalent dose, mg     11.3 ± 8.3    10.5 ± 7.1   0.09
                                                               Titration to target dose, No. (%)   44 (3.1)      25 (1.8)     0.03
  β-blocker at discharge                                                                                                      
                           Carvedilol equivalent dose, mg      16.2 ± 15.9                         16.0 ± 16.9   0.82         
                           Titration to target dose, No. (%)   66 (4.7)                            51 (3.8)      0.25         
  MRA at discharge                                                                                                            
                           MRA dose, mg                        23.8 ± 13.3                         24.2 ± 14.5   0.56         

AHF = acute heart failure, ADCHF = acutely decompensated chronic heart failure, ACEI = angiotensin-converting enzyme inhibitor, ARB = angiotensin-receptor II blocker, MRA = mineralocorticoid receptor antagonists.

Adherence to guideline-directed therapy-outcome link in *de novo* AHF
---------------------------------------------------------------------

The 60-day event free survival curves for each guideline-directed therapy are illustrated in [Fig. 2](#F2){ref-type="fig"}. After adjustment for clinical risk factors, ACEI or ARB at discharge significantly reduced re-hospitalization (HR, 0.57; 95% CI, 0.34--0.95), mortality (HR, 0.41; 95% CI, 0.24--0.69), and composite endpoint (HR, 0.52; 95% CI, 0.36--0.77) rates during the 6-month follow-up period. Beta-blockers had a protective effect against re-hospitalization (HR, 0.62; 95% CI, 0.41--0.95) and composite endpoint (HR, 0.65; 95% CI, 0.47--0.90), but the effect on mortality was not significant (HR, 0.67; 95% CI, 0.42--1.06). After multivariate adjustment, MRA was not associated with any of the endpoints ([Table 3](#T3){ref-type="table"}).

![60-day event free survival according to the adherence of performance measures at discharge in *de novo* HF (blue line: with adherence, red line: without adherence).\
ACEI = angiotensin-converting enzyme inhibitor, ARB = angiotensin receptor II blocker, MRA = mineralocorticoid receptor antagonists, HF = heart failure.](jkms-34-e133-g002){#F2}

###### Risk-adjusted performance measures-outcome link

![](jkms-34-e133-i003)

  Variables     *De novo* heart failure   Acute decompensated heart failure                                  
  ------------- ------------------------- ----------------------------------- ---------- ------------------- ------
  ACEI or ARB                                                                                                
                Rehospitalization         0.57 (0.34--0.95)                   0.03       1.05 (0.74--1.51)   0.77
                Mortality                 0.41 (0.24--0.69)                   \< 0.001   0.58 (0.38--0.89)   0.01
                Composite end point       0.52 (0.36--0.77)                   \< 0.001   0.83 (0.63--1.10)   0.20
  β-blocker                                                                                                  
                Rehospitalization         0.62 (0.41--0.95)                   0.03       0.75 (0.55--1.01)   0.06
                Mortality                 0.67 (0.42--1.06)                   0.09       0.67 (0.45--1.01)   0.06
                Composite end point       0.65 (0.47--0.90)                   0.01       0.71 (0.55--0.91)   0.01
  MRA                                                                                                        
                Rehospitalization         0.89 (0.57--1.39)                   0.61       0.86 (0.63--1.17)   0.33
                Mortality                 1.03 (0.63--1.67)                   0.92       0.83 (0.55--1.24)   0.36
                Composite end point       0.99 (0.70--1.39)                   0.94       0.84 (0.65--1.08)   0.16

Multivariable Cox regression adjusted for gender, age, history of hypertension, diabetes mellitus, ischemic heart disease, chronic obstructive pulmonary disease, New York Heart Association functional class, systolic blood pressure, heart rate, creatinine, atrial fibrillation at admission and left ventricular ejection fraction.

HR = hazard ratio, CI = confidence interval, ACEI = angiotensin-converting enzyme inhibitor, ARB = angiotensin-receptor II blocker, MRA = mineralocorticoid receptor antagonists.

Adherence to guideline-directed therapy-outcome link in ADCHF
-------------------------------------------------------------

[Fig. 3](#F3){ref-type="fig"} shows the Kaplan-Meier curves for each outcome according to each guideline-directed therapy for 60 days after discharge in ADCHF. After multivariable adjustment, the use of ACEI or ARB at discharge was significantly associated with mortality (HR, 0.58; 95% CI, 0.38--0.89). β-blockers reduced the risk of 60-day composite endpoint (HR, 0.71; 95% CI, 0.55--0.91), but their protective effect on re-hospitalization (HR, 0.75; 95% CI, 0.55--1.01) and mortality (HR, 0.67; 95% CI, 0.45--1.01) did not reach statistical significance. There was no association between MRA and any of the endpoints ([Table 3](#T3){ref-type="table"}).

![60-day event free survival according to the adherence of performance measures at discharge in ADCHF (blue line: with adherence, red line: without adherence).\
ACEI = angiotensin-converting enzyme inhibitor, ARB = angiotensin receptor II blocker, MRA = mineralocorticoid receptor antagonists, ADCHF = acute decompensated chronic heart failure.](jkms-34-e133-g003){#F3}

DISCUSSION
==========

In this analysis, baseline characteristics of patients admitted due to AHF were significantly different according to the temporal course of heart failure. The guideline-recommended therapy at discharge, including ACEI/ARB or β-blockers, was associated with improvements in 60-day prognosis in patients with *de novo* AHF, except that β-blockers did not improve the 60-day mortality. In patients with ADCHF, ACEI/ARB was associated with mortality and β-blockers with composite endpoint. MRA had no effect on the prognosis in both types of HF.

*De novo* HF is different from ADCHF
------------------------------------

AHF has two forms: newly arisen ("*de novo*") acute HF and ADCHF according to the temporal course. The differences in baseline characteristics and prognoses in *de novo* AHF and ADCHF are well-established.[@B17] In the EuroHeart Failure Survey (EHFS) II, patients with a previous history of HF had worse long-term prognoses than those with *de novo* AHF, and concomitant diseases are more common in patients with ADCHF.[@B3] In concordance with a previous study, our study identified important differences in prognoses for different types of HF. Patients with a previous history of HF had worse long-term prognosis than those with *de novo* AHF. Importantly, concomitant diseases are more common in patients with ADCHF than those in patients with *de novo* AHF. Thus, ADCHF is associated with more severe symptoms, LV dysfunction, and worse prognosis than *de novo* HF, and these 2 conditions should be kept distinct.

Guideline-directed therapy in the time course of heart failure
--------------------------------------------------------------

It is well established that cardiac dysfunction is generally progressive even when there are no signs and symptoms of HF. The progression of heart failure is associated with left ventricular remodeling, which manifests as gradual increases in left ventricular end-diastolic and end-systolic volumes, wall thinning, and a change in chamber geometry. Due to continuous maladaptive remodeling, myocardial dysfunction is usually a progressive condition, where even mild initial dysfunction may develop into severe HF over a time course of months to years.[@B18] Neurohormonal activation including the sympathetic nervous system and renin angiotensin system in HF is known to be a major mediator of the remodeling process.[@B19] Therapeutic manipulation of these pathways with β-blockers, ACEIs, ARBs, and MRA has become the cornerstone of the management of HF. Consequently, early initiation of these neurohumoral pathway modulators may prevent or slow ventricular remodeling.[@B20][@B21] In acute myocardial infarction, the mortality reduction effect of ACEIs early in the course of treatment is proved in a previous study. In a systematic overview of individual data from 96,712 acute myocardial infarction patients, 30-day mortality was 7.1% among patients allocated to early initiation of ACE Is and 7.6% among control subjects, corresponding to a 7% (SD, 2%) proportional reduction (95% CI, 2%--11%; *P* = 0.004).[@B22] In the Carvedilol Post Infarction Survival Control in left ventricular dysfunction (CAPRICORN) study that enrolled patients with myocardial infarction occurring 3--21 days before randomization; all-cause mortality alone was lower in the carvedilol group than that in the placebo group (HR, 0.77; 95% CI, 0.60--0.98; *P* = 0·03).[@B23] At 6 months, left ventricular end systolic volume was 9.2 mL less in the carvedilol group than that in the placebo group (*P* = 0.023), and left ventricular ejection fraction was 3.9% higher (*P* = 0.015).[@B24]

In HF, there were some data that support the efficacy, safety, and tolerability of beginning β blockers early in patients presenting with clinical signs and symptoms of HF.[@B25][@B26][@B27] But those studies included patients with a diagnosis of chronic HF at least 3 months prior and did not include *de novo* HF. There have been few studies to evaluate the prognostic implications of guideline-directed therapy according to the temporal course of HF. In this study, the beneficial effect of guideline directed therapy was more pronounced in *de novo* HF. However, we could not identify the pathophysiologic explanation for the difference in prognoses according to the time course of HF. There are possible assumptions for the explanation. First, because early initiation of neurohumoral pathway modulators may prevent or slow ventricular remodeling, guideline-directed therapy in the early course of the disease has more noticeable prognostic implication. Second, the beneficial effect of neurohumoral modulators in ADCHF may simply reflect that the efficacy of therapy is modest once a patient undergoes decompensation while on chronic therapy.

The usefulness of aldosterone receptor antagonists in the setting of acute decompensated heart failure has not been determined. Current evidence from randomized aldactone evaluation study (RALES) supporting the use of aldosterone receptor antagonists is based on long-term clinical outcome data, but the acute effects of these agents are less established.[@B28] In contrast to data from the RALES, there was conflicting results of the prognostic implications of MRA.[@B8][@B9] ACCF/AHA/AMA-PCPI 2011 performance measures for adults with heart failure did not adapt MRA as performance measures.[@B29] MRA was not associated with prognosis in both heart failure groups in this study.

Some limitations of our study merit emphasis. First, treatment options are entirely dependent on the attending physician in the KorAHF registry; so, selection bias may exist. Risk-treatment mismatch is present in the guideline-directed therapy. ADCHF is associated with increased comorbidity and deteriorated cardiac function; hence, patients with ADCHF were at increased risk of death. However, rates of treatment with guideline-directed therapy were low in high-risk patients. Second, the influence of background therapy and dose of each guideline-directed therapy were not analyzed because of the limited number of subjects. Third, because adherence to guidelines was defined irrespective of whether therapy was prescribed at discharge, the doses of therapy may not be reflected in this analysis. Fourth, HF duration may have influenced prognosis; however, we have no data regarding HF duration in patients with ADCHF. Finally, drug adherence during follow up period also may have an impact on the prognosis; however, this was not considered in the present study.

In conclusion, the 2 forms of HF are distinct with regard to baseline characteristics, comorbidity, and prognosis. The prognostic implications of adherence to guideline-directed therapy at discharge were more pronounced in *de novo* HF. We recommend that guideline-directed therapy be started as early as possible in the course of HFrEF.
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